Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502, our ...
Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
Expert Rev Clin Immunol. 2008;4(3):379-390. Since there are no genetic deficiencies of CRP in man, animal models have been used to study the role of CRP in inflammatory disease. Two methods have been ...
With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...
4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results